NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Touché

I asked ChatGPT to analyze the process and give me "the odds", which DC's are used.

Bad odds for ex. Again 🤭

To determine which dendritic cell (DC) vaccine is being used in the study you referenced, I'll evaluate the key details and process described in the article (freeze/thaw cycle, broad antigen presentation, tumor lysate approach) and compare them to known DC vaccines.

Process from the Article:

Freeze/Thaw Cycle:
This is a method to process tumor tissue to release a broad spectrum of tumor antigens.

Broad Antigen Presentation:
The focus appears to be on presenting multiple antigens rather than pre-selecting specific ones.

Autologous Tumor Lysate:
Implies the vaccine uses the patient's own tumor tissue to create a personalized antigen source.

Key Comparison:

DCVax-L (Northwest Biotherapeutics):

Uses autologous tumor lysate, processed via a freeze/thaw cycle.

Presents a broad spectrum of antigens to the immune system.

Specifically developed for glioblastoma but is adaptable to other cancers.

Matches the process described in the article closely.

ICT-107 (ImmunoCellular Therapeutics):

Uses pre-selected synthetic peptides rather than tumor lysate.

Targets specific antigens like HER2 and gp100, not a broad antigen spectrum.

Less likely to match the described process.

Neoantigen-Based DC Vaccines:

Focus on personalized neoantigens derived from sequencing the tumor's unique mutations.

Do not typically use a freeze/thaw cycle or tumor lysate.

Process differs significantly from the article's description.

DC vaccines using allogeneic tumor lysates:

Employ lysates from tumor cell lines, not the patient's tumor.

May use a freeze/thaw process but lack the personalized approach of autologous lysate.
Some overlap in method, but less likely given the focus on individual tumors.

DCVax-Direct:

Similar approach to DCVax-L but involves injecting dendritic cells directly into the tumor.

Process doesn't rely on ex vivo preparation with tumor lysate.

Unlikely to be the vaccine in question.

Odds and Analysis:

Given the description of the process in the article (freeze/thaw cycle, broad antigen presentation, autologous tumor lysate), DCVax-L is by far the closest match. Its established methodology aligns almost identically with the described vaccine's preparation and function.

Likelihood assessment:

DCVax-L: 90%
ICT-107: 5%
Neoantigen-Based DC Vaccines: 3%
Allogeneic Tumor Lysate DC Vaccines: 2%
DCVax-Direct: <1%

The process strongly suggests DCVax-L or a very similar vaccine employing autologous tumor lysate and freeze/thaw methods to present multiple tumor antigens. If this is not DCVax-L, it is highly likely inspired by its methodology.